We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

161 hedge funds and large institutions have $712M invested in Aimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more call options, than puts

Call options by funds: $6.47M | Put options by funds: $5.23M

21% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 38

4% more funds holding

Funds holding: 155 → 161 (+6)

4% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 45

55% less capital invested

Capital invested by funds: $1.57B → $712M (-$858M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
161
Holders Change
+6
Holders Change %
+3.87%
% of All Funds
3.55%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
46
Increased
43
Reduced
45
Closed
38
Calls
$6.47M
Puts
$5.23M
Net Calls
+$1.25M
Net Calls Change
-$6.72M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$41.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$39.5M
3
NCM
Nantahala Capital Management
Connecticut
+$25.7M
4
EAM
Eventide Asset Management
Massachusetts
+$19.6M
5
AC
Armistice Capital
New York
+$15.3M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$51.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$40.4M
3
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$32.6M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$11M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
176
Guggenheim Capital
Illinois
– -$335K -10,008 Closed
AIM
177
Aigen Investment Management
New York
– -$319K -9,535 Closed
Principal Financial Group
178
Principal Financial Group
Iowa
– -$306K -9,148 Closed
AG
179
Aperio Group
California
– -$305K -9,124 Closed
ACM
180
AlphaCrest Capital Management
New York
– -$301K -9,000 Closed
CCIA
181
Campbell & Co Investment Adviser
Maryland
– -$283K -8,459 Closed
AB
182
Amalgamated Bank
New York
– -$282K -8,438 Closed
XK
183
Xact Kapitalforvaltning
Sweden
– -$271K -8,100 Closed
LPL Financial
184
LPL Financial
California
– -$266K -7,944 Closed
PPW
185
Parcion Private Wealth
Washington
– -$234K -6,984 Closed
PFS
186
Prospera Financial Services
Texas
– -$228K -6,803 Closed
BFM
187
Boothbay Fund Management
New York
– -$222K -6,640 Closed
CIA
188
Capital Investment Advisors
Georgia
– -$201K -6,000 Closed
CM
189
Caption Management
Oklahoma
– -$167K -5,000 Closed
MA
190
MYDA Advisors
New York
– -$134K -4,000 Closed
OIA
191
Optimum Investment Advisors
Illinois
– -$84K -2,500 Closed
IAS
192
IMA Advisory Services
Colorado
– -$14K -432 Closed
EW
193
Evoke Wealth
California
– -$9.94K -297 Closed
HMS
194
Hanseatic Management Services
New Mexico
– -$3K -87 Closed
GWS
195
Glassman Wealth Services
Virginia
– -$1K -19 Closed
VCM
196
Versant Capital Management
Arizona
– +$1.18K +46 New
4 5 6 7
8

AIMT Hedge Fund Activity: Q1 2020 in Review

161 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2020, worth a combined $712M — down 55% from $1.57B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new AIMT positions and 38 closed out — a net gain of 8 holders — while 43 added to existing stakes and 45 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $41.8M. The largest seller was AllianceBernstein, cutting an estimated $51.1M.

  • 161 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2020, up from 155 in Q4 2019.
  • Funds reported $712M of Aimmune Therapeutics stock for Q1 2020, down 55% quarter-over-quarter.
  • 46 funds opened new Aimmune Therapeutics positions in Q1 2020 and 38 closed out, a net change of +8 holders.
  • The largest Aimmune Therapeutics buyer in Q1 2020 was Victory Capital Management, an estimated $41.8M added.
  • The largest Aimmune Therapeutics seller in Q1 2020 was AllianceBernstein, an estimated $51.1M sold.

Based on aggregated 13F filings for Q1 2020.